Block Grant R43DE018583

This $672,394.58 project grant from the National Institutes of Health's National Institute of Dental and Craniofacial Research Oral Diseases and Disorders Research program (CFDA 93.121) supports the development of a crosslinkable tissue particle implant for regenerating craniofacial bone. Led by Leefa Biotech LLC, the one-year award aims to demonstrate improved bone regeneration in critical-size cranial bone defects using the implant compared to the current standard of care. If successful, the...

This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain. While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes,...

WNT Scientific LLC received a $314,363 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), with an award date of September 16, 2025, and completion date of August 31, 2026. The project focuses on developing an intraarticular injectable disease-modifying osteoarthritis drug (DMOAD) formulation by encapsulating sclerostin, a Wnt signal inhibitor, to create a...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will provide $429,000.00 to the Regents of the University of Michigan to conduct research on the unique characteristics of jawbone biology. The research aims to gain a molecular-level understanding of how osteoblasts in the jawbone respond differently to bone morphogenetic protein (BMP) signaling and mechanical loading...

Federal Grant Award Summary Matregenix Inc. received a $1.952 million Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded July 1, 2025, with completion scheduled for June 30, 2027. The award funds Phase II development and validation of MATRINOVA, an animal-free, amino acid-based bilayered barrier membrane designed for guided bone regeneration (GBR) in oral and craniomaxillofacial...

Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...

Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded The Ohio State University a Project Grant of $469,207 on February 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct research on pharmacological inhibition of ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) to promote cementum regeneration and restore periodontal function. The research addresses a critical gap in therapeutic approaches for...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $446,875 to support research on the role of a novel G protein-coupled receptor, MRGPRX2, in the development of periodontal disease. The funded research aims to develop two humanized mouse models to study the contribution of MRGPRX2-expressing mast cells to Porphyromonas gingivalis-induced and ligature-induced...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $388,575 Project Grant (R21EB035260) to Rutgers, The State University in New Jersey. The grant, under the NIBIB's "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), aims to develop a platform technology for encapsulating bioactive proteins, such as Bone Morphogenic Protein 2 (BMP-2), within hydrophobic polymer matrices. This will enable the...

Function Therapeutics Inc. received a $499,863 Project Grant award dated September 11, 2025, from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate parmodulins—a novel class of small-molecule therapeutics—for treating neuropathic pain. The project, which extends through August 31, 2027, focuses on synthesizing and testing parmodulins that allosterically modify protease-activated receptor...